Publications by authors named "Jordan L Whatley"

Article Synopsis
  • Monovalent and bivalent COVID-19 vaccines containing the Omicron XBB.1.5 variant were approved for use during the 2023-2024 immunization season and are currently undergoing evaluation in a phase 2/3 study.
  • Among participants who previously received previous vaccine doses, those who received the monovalent vaccine showed greater increases in neutralizing antibodies against various SARS-CoV-2 variants compared to those who received the bivalent vaccine.
  • The results indicate that the XBB.1.5 mRNA vaccines generate strong immune responses against newer variants, validating the update of COVID-19 vaccines to include the XBB.1.5 spike protein.
View Article and Find Full Text PDF
Article Synopsis
  • A phase 2/3 trial compared the safety and effectiveness of the new bivalent mRNA-1273.222 vaccine, targeting Omicron BA.4/BA.5 variants, against the original mRNA-1273 vaccine used as boosters in adults who had previously received it.
  • Results showed that the bivalent vaccine produced stronger neutralizing antibody responses against the Omicron variants while maintaining similar effectiveness against the original virus compared to mRNA-1273.
  • The safety profile for mRNA-1273.222 was consistent with the previous vaccine, with no new safety issues found, but further monitoring of vaccine effectiveness and potential new variants is advised.
View Article and Find Full Text PDF